Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP

Summary Aim: Rhenium-188-HEDP (188Re-HEDP) is an effective radiopharmaceutical for the palliative treatment of osteoblastic bone metastases. However, only limited data on its routine use are available and its effect on quality of life (QoL) has not been studied. Therefore, we evaluated the clinical benefit of 188Re-HEDP in routine clinical care. Patients and methods: Prostate or breast cancer patients with painful bone metastases receiving 188Re-HEDP as a routine clinical procedure were eligible for evaluation. Clinical benefit was assessed in terms of efficacy and toxicity. Pain palliation and QoL were monitored using the visual analogue scale (VAS), corrected for opioid intake, and the EORTC QLQ-C30 Global health status/QoL-scale. Thrombocyte and leukocyte nadirs were used to assess haematological toxicity. Results: 45 and 47 patients were evaluable for pain palliation and QoL, respectively. After a single injection of 188Re-HEDP, the overall pain response rate was 69% and mean VAS-scores decreased relevantly and significantly (p < 0.05). Repeated treatment resulted in similar pain response. The overall QoL response rate was 68% and mean Global health status/QoL-scores increased relevantly and significantly. Haematological side effects were mild and transient. Conclusion: The clinically relevant response on pain and quality of life and the limited adverse events prove clinical benefit of treatment with 188Re-HEDP and support its use in routine clinical care. Its effectiveness appears comparable to that of external beam radiotherapy.

Download Full-text

Quality of Life in Relation to Pain Response to Radiation Therapy for Painful Bone Metastases

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2015.06.024 ◽

2015 ◽

Vol 93 (3) ◽

pp. 694-701 ◽

Cited By ~ 28

Author(s):

Paulien G. Westhoff ◽

Alexander de Graeff ◽

Evelyn M. Monninkhof ◽

Jacqueline Pomp ◽

Marco van Vulpen ◽

...

Keyword(s):

Quality Of Life ◽

Radiation Therapy ◽

Bone Metastases ◽

Pain Response ◽

Painful Bone Metastases

Download Full-text

Quality of Life for Children with Persistent Sinonasal Symptoms

Otolaryngology ◽

10.1067/mhn.2003.41 ◽

2003 ◽

Vol 128 (1) ◽

pp. 17-26 ◽

Cited By ~ 97

Author(s):

David J. Kay ◽

Richard M. Rosenfeld

Keyword(s):

Quality Of Life ◽

Clinical Care ◽

Longitudinal Change ◽

Good Test ◽

Routine Clinical Care ◽

Before And After ◽

The Mean ◽

The Individual ◽

Sinonasal Symptoms

OBJECTIVE: The goal was to validate the SN-5 survey as a measure of longitudinal change in health-related quality of life (HRQoL) for children with persistent sinonasal symptoms. DESIGN AND SETTING: We conducted a before and after study of 85 children aged 2 to 12 years in a metropolitan pediatric otolaryngology practice. Caregivers completed the SN-5 survey at entry and at least 4 weeks later. The survey included 5 symptom-cluster items covering the domains of sinus infection, nasal obstruction, allergy symptoms, emotional distress, and activity limitations. RESULTS: Good test-retest reliability ( R = 0.70) was obtained for the overall SN-5 score and the individual survey items ( R ≥ 0.58). The mean baseline SN-5 score was 3.8 (SD, 1.0) of a maximum of 7.0, with higher scores indicating poorer HRQoL. All SN-5 items had adequate correlation ( R ≥ 0.36) with external constructs. The mean change in SN-5 score after routine clinical care was 0.88 (SD, 1.19) with an effect size of 0.74 indicating good responsiveness to longitudinal change. The change scores correlated appropriately with changes in related external constructs ( R ≥ 0.42). CONCLUSIONS: The SN-5 is a valid, reliable, and responsive measure of HRQoL for children with persistent sinonasal symptoms, suitable for use in outcomes studies and routine clinical care.

Download Full-text

Radiotherapy plus either transdermal fentanyl or paracetamol and codeine for painful bone metastases: a randomised study of pain relief and quality of life

Current Medical Research and Opinion ◽

10.1185/030079903125002829 ◽

2004 ◽

Vol 20 (2) ◽

pp. 159-163 ◽

Cited By ~ 11

Author(s):

Kyriaki Pistevou-Gompaki ◽

Vassilis E. Kouloulias ◽

Charalambos Varveris ◽

Kyriaki Mystakidou ◽

Grigoris Georgakopoulos ◽

...

Keyword(s):

Quality Of Life ◽

Pain Relief ◽

Bone Metastases ◽

Transdermal Fentanyl ◽

Randomised Study ◽

Painful Bone Metastases

Download Full-text

Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain

Journal of Clinical Medicine ◽

10.3390/jcm9082622 ◽

2020 ◽

Vol 9 (8) ◽

pp. 2622 ◽

Cited By ~ 1

Author(s):

Reyhaneh Manafi-Farid ◽

Fardad Masoumi ◽

Ghasemali Divband ◽

Bahare Saidi ◽

Bahar Ataeinia ◽

...

Keyword(s):

Radionuclide Therapy ◽

Bone Pain ◽

Response Rate ◽

Pain Palliation ◽

Simultaneous Treatment ◽

Bone Pain Palliation ◽

Wide Range ◽

Metastatic Bone Pain ◽

Multiple Bone Metastases

Bone metastasis develops in multiple malignancies with a wide range of incidence. The presence of multiple bone metastases, leading to a multitude of complications and poorer prognosis. The corresponding refractory bone pain is still a challenging issue managed through multidisciplinary approaches to enhance the quality of life. Radiopharmaceuticals are mainly used in the latest courses of the disease. Bone-pain palliation with easy-to-administer radionuclides offers advantages, including simultaneous treatment of multiple metastatic foci, the repeatability and also the combination with other therapies. Several β¯- and α-emitters as well as pharmaceuticals, from the very first [89Sr]strontium-dichloride to recently introduced [223Ra]radium-dichloride, are investigated to identify an optimum agent. In addition, the combination of bone-seeking radiopharmaceuticals with chemotherapy or radiotherapy has been employed to enhance the outcome. Radiopharmaceuticals demonstrate an acceptable response rate in pain relief. Nevertheless, survival benefits have been documented in only a limited number of studies. In this review, we provide an overview of bone-seeking radiopharmaceuticals used for bone-pain palliation, their effectiveness and toxicity, as well as the results of the combination with other therapies. Bone-pain palliation with radiopharmaceuticals has been employed for eight decades. However, there are still new aspects yet to be established.

Download Full-text

Health-related quality of life measures in routine clinical care: Can FACT-Fatigue help to assess the management of fatigue in cancer patients?

International Journal of Technology Assessment in Health Care ◽

10.1017/s0266462309090126 ◽

2009 ◽

Vol 25 (01) ◽

pp. 90-96 ◽

Cited By ~ 12

Author(s):

Maria-Jose Santana ◽

Heather-Jane Au ◽

Melina Dharma-Wardene ◽

Joanne D. Hewitt ◽

David Dupere ◽

...

Keyword(s):

Quality Of Life ◽

Cancer Patients ◽

Clinical Care ◽

Health Related Quality ◽

Routine Clinical Care ◽

Study Results ◽

Related Quality ◽

Health Related

Objectives:Fatigue is the most common symptom reported by cancer patients. The inclusion of health-related quality of life (HRQL) measures in routine clinical care of cancer patients may improve the management of fatigue. The primary objective of this study is to provide evidence on the magnitude of change in fatigue subscale scores using the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) that is clinically important.Methods:Consecutive patients with advanced primary lung cancer attending a Canadian tertiary care cancer and, prior to undergoing palliative chemotherapy, were enrolled in the study. Patients completed a battery of questionnaires [FACT-F, Qualitative Patients Self-report of Fatigue Level (QPSRF)] at baseline, follow-up and 2 weeks after their final cycle of chemotherapy. Clinicians assessed the patients using the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale at baseline and each follow-up visit. FACT-F change scores were computed as the mean change in score (end of study score minus baseline score).Results:A total of 43 patients with mean age of 59 years were enrolled in the study. Results revealed a mean change in FACT-F subscale score of 5.0 (SE 1.06) for those who rated themselves as more tired, 1.28 (SE 1.00) for those who rated themselves as the same (no change), and −1.52 (SE 0.84) for those patients who rated themselves as less tired.Conclusions:We provide evidence on the magnitude of change in FACT-F score that is associated with the perception by patients of improvement in fatigue and magnitude of change in score that is associated with worsening in fatigue.

Download Full-text